Loading...
XNYS
ZBH
Market cap18bUSD
Jul 11, Last price  
93.79USD
1D
-1.43%
1Q
-8.36%
Jan 2017
-9.12%
IPO
233.77%
Name

Zimmer Biomet Holdings Inc

Chart & Performance

D1W1MN
P/E
20.53
P/S
2.42
EPS
4.57
Div Yield, %
0.77%
Shrs. gr., 5y
-0.27%
Rev. gr., 5y
-0.77%
Revenues
7.68b
+3.85%
3,286,100,0003,495,400,0003,897,500,0004,121,100,0004,095,400,0004,220,200,0004,451,800,0004,471,700,0004,623,400,0004,673,300,0005,997,800,0007,683,900,0007,824,100,0007,932,900,0007,982,200,0007,024,500,0006,827,300,0006,939,900,0007,394,200,0007,678,600,000
Net income
904m
-11.74%
732,500,000834,500,000773,200,000848,600,000717,400,000596,900,000760,800,000755,000,000761,000,000720,100,00049,700,000302,900,0001,839,600,000-379,200,0001,131,600,000-137,400,000401,600,000231,400,0001,024,000,000903,800,000
CFO
1.50b
-5.20%
878,200,0001,040,700,0001,084,400,0001,038,100,0001,117,500,0001,193,500,0001,176,900,0001,151,900,000963,100,0001,052,800,000862,800,0001,632,200,0001,582,300,0001,747,400,0001,585,800,0001,204,500,0001,499,200,0001,284,700,0001,581,600,0001,499,400,000
Dividend
Sep 30, 20240.24 USD/sh
Earnings
Aug 05, 2025

Profile

Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. The company is headquartered in Warsaw Indiana, Indiana and currently employs 19,000 full-time employees. The firm's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The firm manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The firm's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
IPO date
Jul 25, 2001
Employees
18,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,678,600
3.85%
7,394,200
6.55%
6,939,900
1.65%
Cost of revenue
2,628,600
2,542,500
2,425,500
Unusual Expense (Income)
NOPBT
5,050,000
4,851,700
4,514,400
NOPBT Margin
65.77%
65.61%
65.05%
Operating Taxes
131,400
42,200
112,300
Tax Rate
2.60%
0.87%
2.49%
NOPAT
4,918,600
4,809,500
4,402,100
Net income
903,800
-11.74%
1,024,000
342.52%
231,400
-42.38%
Dividends
(196,000)
(200,900)
(201,200)
Dividend yield
0.91%
0.79%
0.75%
Proceeds from repurchase of equity
(868,000)
(692,200)
(48,300)
BB yield
4.03%
2.71%
0.18%
Debt
Debt current
863,000
952,900
544,300
Long-term debt
5,341,600
5,216,700
5,319,500
Deferred revenue
Other long-term liabilities
744,100
751,400
1,053,800
Net debt
5,679,100
5,722,200
5,471,500
Cash flow
Cash from operating activities
1,499,400
1,581,600
1,284,700
CAPEX
(203,800)
(602,800)
(187,900)
Cash from investing activities
(888,100)
(778,900)
(529,200)
Cash from financing activities
(484,500)
(763,500)
(843,800)
FCF
4,926,300
4,305,100
4,280,400
Balance
Cash
525,500
415,800
375,700
Long term investments
31,600
16,600
Excess cash
141,570
77,690
45,305
Stockholders' equity
10,843,800
10,204,400
9,389,800
Invested Capital
19,283,330
19,157,110
18,694,495
ROIC
25.59%
25.41%
22.19%
ROCE
25.53%
24.76%
23.50%
EV
Common stock shares outstanding
203,900
209,700
210,300
Price
105.63
-13.20%
121.70
-4.55%
127.50
0.36%
Market cap
21,537,957
-15.61%
25,520,490
-4.82%
26,813,250
0.31%
EV
27,225,157
31,250,390
32,291,450
EBITDA
6,046,300
5,803,400
5,440,800
EV/EBITDA
4.50
5.38
5.94
Interest
218,000
201,200
164,800
Interest/NOPBT
4.32%
4.15%
3.65%